Literature DB >> 18824923

Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis.

Kari K Eklund1, Ken Lindstedt, Charlotta Sandler, Petri T Kovanen, Leena Laasonen, Annika Juurikivi, Henrik Wolff, Marko Mykkänen, Heikki Joensuu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18824923     DOI： 10.1097/RHU.0b013e318188b1ce

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN： 1076-1608            Impact factor:   3.517


× No keyword cloud information.
  8 in total

Review 1.  Tyrosine kinases in inflammatory dermatologic disease.

Authors:  Ricardo T Paniagua; David F Fiorentino; Lorinda Chung; William H Robinson
Journal:  J Am Acad Dermatol       Date:  2010-06-26       Impact factor: 11.527

Review 2.  Cellular targeting in autoimmunity.

Authors:  Jennifer L Rogers; Donald S Serafin; Roman G Timoshchenko; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

3.  A multitude of kinases--which are the best targets in treating rheumatoid arthritis?

Authors:  Tamsin M Lindstrom; William H Robinson
Journal:  Rheum Dis Clin North Am       Date:  2010-05       Impact factor: 2.670

4.  Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages.

Authors:  Emileigh K Greuber; Ann Marie Pendergast
Journal:  J Immunol       Date:  2012-10-24       Impact factor: 5.422

5.  Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice.

Authors:  Chin Kook Rhee; Sang Haak Lee; Hyung Kyu Yoon; Seok Chan Kim; Sook Young Lee; Soon Suk Kwon; Young Kyoon Kim; Kwan Hyoung Kim; Tae Jung Kim; Jin Woo Kim
Journal:  Respiration       Date:  2011-06-09       Impact factor: 3.580

6.  A computational approach to finding novel targets for existing drugs.

Authors:  Yvonne Y Li; Jianghong An; Steven J M Jones
Journal:  PLoS Comput Biol       Date:  2011-09-01       Impact factor: 4.475

7.  Imatinib might constitute a treatment option for lung involvement in COVID-19.

Authors:  David Bernal-Bello; Beatriz Jaenes-Barrios; Alejandro Morales-Ortega; José Manuel Ruiz-Giardin; Virginia García-Bermúdez; Begoña Frutos-Pérez; Ana Isabel Farfán-Sedano; Cristina de Ancos-Aracil; Fernando Bermejo; Mario García-Gil; Antonio Zapatero-Gaviria; Juan Víctor San Martín-López
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

8.  Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery.

Authors:  In Kyoung Kim; Chin Kook Rhee; Chang Dong Yeo; Hyeon Hui Kang; Dong Gun Lee; Sang Haak Lee; Jin Woo Kim
Journal:  Crit Care       Date:  2013-06-20       Impact factor: 9.097
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.